Draeger Wins FDA Nod for Advancements to Evita V800 Ventilator

Draeger has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest advancements to its Evita V800 ventilator. The 3.10 software release’s clearance gives V800 additional features to enhance mechanical ventilation for patients suffering from pulmonary disease like ARDS.

It decelerates flow during volume control ventilation, offering clinician-controlled flow to match patient demand with recommended ARDSnet safeguards. Guidance maps for low and high PEEP-FiO2 tables facilitate clinicians’ decision making in determining the best FEEP and FiO2 settings.

It can also calculate driving pressure and semi-automated static compliance to help clinicians manage inspiratory settings, which can possible reduce risk of ventilator-induced lung injury (VILI).

“Dräger continues to be on the forefront of technology, the addition of these new features for the Evita V800 is another example of Dräger’s commitment to research and development for respiratory care,” said Lothar Thielen, president and CEO of Draeger, Inc. “Dräger is proud to again serve our customers with the latest technology.”